Logo Logo

Category Archives: "INforMS"

  1. Home
  2. INforMS
Apr 17, 2024
Press Release: New 48-Week Frexalimab Phase 2 Data Support Potential For High Sustained Efficacy In Multiple Sclerosis
INforMS, News
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a [...]
Elizabeth Porco
Read More
...12
0
Feb 29, 2024
The Siegel Rare Neuroimmune Association Marks 30 Years of Improving Quality of Life for People With Rare Neuroimmune Disorders
INforMS, News
Not-for-profit celebrates past achievements and looks to the future POWELL, Ohio, February 29, 2024 (Newswire.com) - The Siegel Rare [...]
Elizabeth Porco
Read More
...12
0
Jan 23, 2024
The Language of MS: How Much Does It Matter?
INforMS, News
I got an email recently from someone well up the chain of command at a multiple sclerosis (MS) patient advocacy organization. The purpose [...]
Elizabeth Porco
Read More
...16
0
Oct 11, 2023
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
INforMS, Partners
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete [...]
Elizabeth Porco
Read More
...25
0
Jul 17, 2023
Positive Phase III results for Genentech’s Ocrevus (ocrelizumab)
INforMS, Partners
Phase III OCARINA II trial met primary and secondary endpoints Ocrevus 10-minute injection has the potential to further improve the [...]
Elizabeth Porco
Read More
...27
0
Jan 11, 2023
Helius launches UpScript telehealth e-commerce site
INforMS, Partners
PDF Version New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps NEWTOWN, Pa., Jan. 03, 2023 [...]
Elizabeth Porco
Read More
...21
0
Dec 12, 2022
Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023
INforMS
Eligible patients will receive full MS patient support program through Cycle Vita™ Boston, Massachusetts and San Jose, California – [...]
Elizabeth Porco
Read More
...19
0
Oct 19, 2022
Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis & NMOSD research at ECTRIMS
INforMS, Partners
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® (ocrelizumab) data and continued [...]
Elizabeth Porco
Read More
...21
0
Aug 16, 2022
US FDA – Ocrevus prescribing information to include warnings for Colitis and PML
INforMS, Partners
Labeling updates to Ocrevus (ocrelizumab) injection, for intravenous use for the treatment of multiple sclerosis (MS) will be [...]
Elizabeth Porco
Read More
...20
0
Apr 21, 2022
Janssen Pharmaceuticals U.S. transparency report
INforMS, Partners
Janssen Pharmaceuticals recently published their sixth annual Janssen U.S. Transparency Report. The Report explains Janssen’s sustained [...]
Elizabeth Porco
Read More
...18
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last

Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM